Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
US-Iran Ceasefire Talks Underway: What You Need to Know 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
U.S. Deploys Elite 82nd Airborne Troops to Middle East Amid Iran Tensions 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Trump Votes by Mail Despite Calling It "Cheating" as Democrat Wins Mar-a-Lago District 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Trump Administration Settles Lawsuit Barring Federal Agencies from Pressuring Social Media Censorship 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Trump Seeks Quick End to U.S.-Iran Conflict Amid Ongoing Middle East Tensions 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
